# Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003

> **NCT02289716** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 41 (actual)

## Conditions studied

- Osteoarthritis
- Pain

## Interventions

- **DRUG:** Placebo
- **DRUG:** Fulranumab 1 mg
- **DRUG:** Fulranumab 3 mg

## Key facts

- **NCT ID:** NCT02289716
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-10
- **Primary completion:** 2016-10-10
- **Final completion:** 2016-10-10
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02289716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02289716, "Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02289716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*